Back HBV Treatment

HBV Treatment

AASLD 2014: Experimental siRNA Therapy Lowers HBsAg Levels in Hepatitis B Patients

ARC-520, a novel therapy using short interfering RNA (siRNA), appeared safe and was associated with a reduction in hepatitis B surface antigen (HBsAg) levels in chronic hepatitis B patients taking entecavir, according to Phase 2a study results reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meetinglast month in Boston.

alt

Read more:

AASLD 2014: Entecavir and Tenofovir Work Well for People with Resistant Hepatitis B Virus

A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the ENTEBE study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Another study, however, showed that for some resistant patients, tenofovir worked equally well on its own.

alt

Read more:

AASLD 2014: Tenofovir Continues to Work Well Against Hepatitis B Virus for 8 Years

Most chronic hepatitis B patients treated with tenofovir (Viread) for 8 years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.Serological response rates continued to increase over time and kidney and bone-related side effects remained uncommon.

alt

Read more:

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt

AASLD 2014: Pegylated Interferon + Tenofovir Improves Odds of HBsAg Loss in Hepatitis B Patients

People with chronic hepatitis B virus (HBV) infection are more likely to experience favorable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir -- although even then the cure rate falls short of 10%, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more: